Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation

British Journal of Pharmacology

Volumn 161, Issue 5, 2010, Pages 1150-1160

  Lecka, Joanna ^a   Rana, Manjit Singh ^a   Sévigny, Jean ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Endothelium; NTPDase1 CD39; P2Y 12 receptors; Platelets; Pro drugs; Thienopyridines

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; ECTO 5' NUCLEOTIDASE; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; NUCLEOTIDASE; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; UMBILICAL VEIN;

5'-NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; HYDROLYSIS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRODRUGS; RATS; SPECIES SPECIFICITY; TICLOPIDINE; UMBILICAL VEINS;

EID: 77958529498     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00951.x     Document Type: Article

References (50)

1. Ajjan R, Grant PJ (2006). Coagulation and atherothrombotic disease. Atherosclerosis 186: 240-259.
2. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Ansari HR, Nadeem A, Talukder MA, Sakhalkar S, Mustafa SJ (2007). Evidence for the involvement of nitric oxide in A2B receptor-mediated vasorelaxation of mouse aorta. Am J Physiol Heart Circ Physiol 292: H719-H725.
4. Armstrong PCJ, Dhanji AR, Tucker AT, Mitchell JA, Warner TD (2009). Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 8: 613-615.
5. Baykov AA, Evtushenko OA, Avaeva SM (1988). A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal Biochem 171: 266-270.
6. Boneu B, Destelle G (1996). Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 76: 939-943.
7. Bradford MM (1976). A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 72: 248-254.
8. Braun OO, Amisten S, Wihlborg AK, Hunting K, Nilsson D, Erlinge D (2007). Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12. Purinergic Signal 3: 195-201.
9. Cattaneo M (2006). ADP receptors: inhibitory strategies for antiplatelet therapy. Timely Top Med Cardiovasc Dis 10: E22.
10. Chinnakotla S, Leone JP, Fidler ME, Hammeke MD, Tarantolo S (2000). Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. Transplantation 70: 550-552.
11. Colgan SP, Holger KE, Eckle T, Thompson LF (2006). Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2: 351-360.
12. Corradi D, Callegari S, Benussi S, Maestri R, Pastori P, Nascimbene S et al. (2005). Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. Hum Pathol 36: 1080-1089.
13. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al. (2001). Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103: 1967-1971.
14. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M (1985). Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 75: 328-338.
15. Duprez DA, Cohn JN (2006). Monitoring vascular health beyond blood pressure. Curr Hypertens Rep 8: 287-291.
16. Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Schulte Am Esch J, II et al. (1999). Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5: 1010-1017.
17. Evens AM, Kwaan HC, Kaufman DB, Bennett CL (2002). TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation 74: 885-887.
18. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE et al. (2001). Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107: 1591-1598.
19. Goldsmith HL, Bell DN, Braovac S, Steinberg A, McIntosh F (1995). Physical and chemical effects of red cells in the shear-induced aggregation of human platelets. Biophys J 69: 1584-1595.
20. Guckelberger O, Sun XF, Sévigny J, Imai M, Kaczmarek E, Enjyoji K et al. (2004). Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 91: 576-586.
21. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM et al. (2006). Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333: 726.
22. Hechler B, Cattaneo M, Gachet C (2005). The P2 receptors in platelet function. Semin Thromb Hemost 31: 150-161.
23. Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V et al. (2001). Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409: 202-207.
24. Hourani SM (1996). Purinoceptors and platelet aggregation. J Auton Pharmacol 16: 349-352.
25. Kaczmarek E, Koziak K, Sévigny J, Siegel JB, Anrather J, Beaudoin AR et al. (1996). Identification and characterization of CD39 vascular ATP diphosphohydrolase. J Biol Chem 271: 33116-33122.
26. Kam PC, Nethery CM (2003). The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 58: 28-35.
27. Kawashima Y, Nagasawa T, Ninomiya H (2000). Contribution of ecto-5'-nucleotidase to the inhibition of platelet aggregation by human endothelial cells. Blood 96: 2157-2162.
28. Koszalka P, Ozuyaman B, Huo Y, Zernecke A, Flogel U, Braun N et al. (2004). Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 95: 814-821.
29. Kukulski F, Lévesque SA, Lavoie EG, Lecka J, Bigonnesse F, Knowles AF et al. (2005). Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 1: 193-204.
30. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM et al. (2005). Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 46: 1833-1837.
31. Lévesque SA, Lavoie EG, Lecka J, Bigonnesse F, Sévigny J (2007). Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases. Br J Pharmacol 152: 141-150.
32. Makkar K, Wilensky RL, Julien MB, Herrmann HC, Spinler SA (2006). Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother 40: 1204-1207.
33. Marcus AJ, Broekman MJ, Drosopoulos JHF, Islam N, Alyonycheva TN, Safier LB et al. (1997). The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99: 1351-1360.
34. Misumi Y, Ogata S, Hirose S, Ikehara Y (1990). Primary structure of rat liver 5'-nucleotidase deduced from the cDNA. Presence of the COOH-terminal hydrophobic domain for possible post-translational modification by glycophospholipid. J Biol Chem 265: 2178-2183.
35. Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ et al. (2005). Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci USA 102: 3782-3787.
36. Motte S, Communi D, Pirotton S, Boeynaems JM (1995). Involvement of multiple receptors in the actions of extracellular ATP: the example of vascular endothelial cells. [Review]. Int J Biochem Cell Biol 27: 1-7.
37. Nadar SK, Lip GY, Blann AD (2004). Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project. Thromb Haemost 92: 1342-1348.
38. Oster G, Huse DM, Lacey MJ, Epstein AM (1994). Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 25: 1149-1156.
39. Pearson JD, Carleton JS, Gordon JL (1980). Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smooth-muscle cells in culture. Biochem J 190: 421-429.
40. Puri KS, Suresh KR, Gogtay NJ, Thatte UM. (2009). Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med 55: 131-134.
41. Quinn MJ, Fitzgerald DJ (1999). Ticlopidine and clopidogrel. Circulation 100: 1667-1672.
42. Ralevic V, Burnstock G (1991). Roles of P2-purinoceptors in the cardiovascular system. Circulation 84: 1-14.
43. Robson SC, Sévigny J, Zimmermann H (2006). The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2: 409-430.
44. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y et al. (1994). The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72: 313-317.
45. Sempere AP, Ferrero M, Tahoces ML, Duarte J, Tabernero C, Cabezas C et al. (2000). [Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease]. Rev Neurol 30: 5-7.
46. Sévigny J, Levesque FP, Grondin G, Beaudoin AR (1997). Purification of the blood vessel ATP diphosphohydrolase, identification and localization by immunological techniques. Biochim Biophys Acta 1334: 73-88.
47. Sévigny J, Sundberg C, Braun N, Guckelberger O, Csizmadia E, Qawi I et al. (2002). Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99: 2801-2809.
48. Vorchheimer DA, Becker R (2006). Platelets in atherothrombosis. Mayo Clin Proc 81: 59-68.
49. Waehre T, Damas JK, Pedersen TM, Gullestad L, Yndestad A, Andreassen AK et al. (2006). Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 4: 2140-2147.
50. Yaar R, Jones MR, Chen JF, Ravid K (2005). Animal models for the study of adenosine receptor function. J Cell Physiol 202: 9-20.